Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Tan, Xiaohong ^a,b,c   Carretero, Julian ^b,c,h   Chen, Zhao ^b,c   Zhang, Jishuai ^a   Wang, Yanxiao ^a   Chen, Jicheng ^a   Li, Xiubin ^a   Ye, Hui ^a   Tang, Chuanhao ^e   Cheng, Xuan ^a   Hou, Ning ^a   Yang, Xiao ^a,d   Wong, Kwok Kin ^b,c,f,g  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

^e BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g Belfer Institute for Innovative Cancer Science   (United States)

^h UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CCL19 PROTEIN, MOUSE; CCL20 PROTEIN, MOUSE; INTERLEUKIN 6; KRAS2 PROTEIN, MOUSE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; PROTEIN P21; PROTEIN P53; STAT3 PROTEIN; STAT3 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; DEFICIENCY; DISEASE COURSE; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; METASTASIS; MORTALITY; MOUSE; MUTATION; NON SMALL CELL LUNG CANCER; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SURVIVAL; TRANSGENIC MOUSE;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOKINE CCL19; CHEMOKINE CCL20; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; LUNG NEOPLASMS; MICE; MICE, TRANSGENIC; MUTATION; NEOPLASM METASTASIS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84894071177     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080885     Document Type: Article

References (52)

1. Ballaz S, Mulshine JL (2003) The potential contributions of chronic inflammation to lung carcinogenesis. Clin Lung Cancer 5: 46-62. doi:10.3816/CLC.2003.n.021. PubMed: 14596704. (Pubitemid 36974741)
2. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357: 539-545. doi:10.1016/S0140-6736(00)04046-0. PubMed: 11229684. (Pubitemid 32173595)
3. Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR (2011) A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther 11: 1663-1668. doi:10.1517/14712598.2011.627850. PubMed: 21995322.
4. Ancrile B, Lim KH, Counter CM (2007) Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 21: 1714-1719. doi:10.1101/gad. 1549407. PubMed: 17639077. (Pubitemid 47076470)
5. Keller ET, Wanagat J, Ershler WB (1996) Molecular and cellular biology of interleukin-6 and its receptor. Front Biosci 1: d340-d357. PubMed: 9159238.
6. Chen J, Liu RY, Yang L, Zhao J, Zhao X et al. (2013) A two-SNP IL-6 promoter haplotype is associated with increased lung cancer risk. J Cancer Res Clin Oncol 139: 231-242. doi:10.1007/s00432-012-1314-z. PubMed: 23052692.
7. Heikkilä K, Harris R, Lowe G, Rumley A, Yarnell J et al. (2009) Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 20: 15-26. doi:10.1007/s10552-008-9212-z. PubMed: 18704713.
8. Bai L, Yu H, Wang H, Su H, Zhao J et al. (2013) Genetic singlenucleotide polymorphisms of inflammation-related factors associated with risk of lung cancer. Med Oncol 30: 414. doi:10.1007/s12032-012-0414-6. PubMed: 23292870.
9. Carpagnano GE, Resta O, Foschino-Barbaro MP, Gramiccioni E, Carpagnano F (2002) Interleukin-6 is increased in breath condensate of patients with non-small cell lung cancer. Int J Biol Markers 17: 141-145. PubMed: 12113582. (Pubitemid 34873801)
10. Yanagawa H, Sone S, Takahashi Y, Haku T, Yano S et al. (1995) Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer 71: 1095-1098. doi:10.1038/bjc.1995.212. PubMed: 7734307.
11. Yeh HH, Lai WW, Chen HH, Liu HS, Su WC (2006) Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 25: 4300-4309. doi:10.1038/sj.onc.1209464. PubMed: 16518408. (Pubitemid 44100500)
12. Yanagawa H, Sone S, Munekata M, Atagi S, Nii A et al. (1992) IL-6 in malignant pleural effusions and its augmentation by intrapleural instillation of IL-2. Clin Exp Immunol 88: 207-212. PubMed: 1315227.
13. Szczesny TJ, Slotwinski R, Stankiewicz A, Szczygiel B, Zaleska M et al. (2007) Interleukin 6 and interleukin 1 receptor antagonist as early markers of complications after lung cancer surgery. Eur J Cardiothorac Surg 31: 719-724. doi:10.1016/j.ejcts.2007.01.027. PubMed: 17317198. (Pubitemid 46400515)
14. Kita H, Shiraishi Y, Watanabe K, Suda K, Ohtsuka K et al. (2011) Does postoperative serum interleukin-6 influence early recurrence after curative pulmonary resection of lung cancer? Ann Thorac Cardiovasc Surg 17: 454-460. doi:10.5761/atcs.oa.10.01627. PubMed: 21881374.
15. Songür N, Kuru B, Kalkan F, Ozdilekcan C, Cakmak H et al. (2004) Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumori 90: 196-200. PubMed: 15237582. (Pubitemid 38745608)
16. Chang CH, Hsiao CF, Yeh YM, Chang GC, Tsai YH et al. (2013) Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int J Cancer 132: 1977-1985. doi:10.1002/ijc.27892. PubMed: 23034889.
17. Koh E, Iizasa T, Yamaji H, Sekine Y, Hiroshima K et al. (2012) Significance of the correlation between the expression of interleukin 6 and clinical features in patients with non-small cell lung cancer. Int J Surg Pathol 20: 233-239. doi:10.1177/1066896911436274. PubMed: 22334615.
18. Ujiie H, Tomida M, Akiyama H, Nakajima Y, Okada D et al. (2012) Serum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancer. Anticancer Res 32: 3251-3258. PubMed: 22843899.
19. Enewold L, Mechanic LE, Bowman ED, Zheng YL, Yu Z et al. (2009) Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 18: 215-222. doi:10.1158/1055-9965. EPI-08-0705. PubMed: 19124500.
20. Tas F, Duranyildiz D, Argon A, Oǧuz H, Camlica H et al. (2005) Serum levels of leptin and proinflammatory cytokines in advanced-stage nonsmall cell lung cancer. Med Oncol 22: 353-358. doi:10.1385/MO: 22:4:353. PubMed: 16260852. doi:10.1385/MO:22:4:353 PubMed: 16260852
21. Martín F, Santolaria F, Batista N, Milena A, González- Reimers E et al. (1999) Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 11: 80-86. doi:10.1006/cyto.1998.0398. PubMed: 10080883. (Pubitemid 29097356)
22. Wojciechowska-Lacka A, Adamiak E, Stryczynska G, Lacki JK (1997) Prognostic value of serial serum interleukin-6 level estimation in patients with lung cancer: a preliminary report. Yale J Biol Med 70: 139-148. PubMed: 9493846. (Pubitemid 28087003)
23. Wójcik E, Jakubowicz J, Skotnicki P, Sas-Korczyńska B, Kulpa JK (2010) IL-6 and VEGF in small cell lung cancer patients. Anticancer Res 30: 1773-1778. PubMed: 20592377.
24. De Vita F, Orditura M, Auriemma A, Infusino S, Roscigno A et al. (1998) Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep 5: 649-652. PubMed: 9538169.
25. Takeuchi E, Ito M, Mori M, Yamaguchi T, Nakagawa M et al. (1996) Lung cancer producing interleukin-6. Intern Med 35: 212-214. doi:10.2169/ internalmedicine.35.212. PubMed: 8785456. (Pubitemid 126462528)
26. Yamaji H, Iizasa T, Koh E, Suzuki M, Otsuji M et al. (2004) Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer. Cancer Immunol Immunother 53: 786-792. PubMed:15185009. (Pubitemid 39149905)
27. Yi H, Cho HJ, Cho SM, Jo K, Park JA et al. (2012) Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells. Int J Oncol 41: 310-316. PubMed: 22552503.
28. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE (2008) Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLOS ONE 3: e3077. doi:10.1371/journal.pone.0003077. PubMed: 18728788.
29. Hsu HS, Lin JH, Hsu TW, Su K, Wang CW et al. (2012) Mesenchymal stem cells enhance lung cancer initiation through activation of IL-6/JAK2/STAT3 pathway. Lung Cancer 75: 167-177. doi:10.1016/j.lungcan.2011.07.001. PubMed: 21802163.
30. Tawara K, Oxford JT, Jorcyk CL (2011) Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res 3: 177-189. PubMed: 21625400.
31. Yang CL, Liu YY, Ma YG, Xue YX, Liu DG et al. (2012) Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway. PLOS ONE 7: e37960. doi:10.1371/journal.pone.0037960. PubMed: 22662257.
32. Ochoa CE, Mirabolfathinejad SG, Ruiz VA, Evans SE, Gagea M et al. (2011) Interleukin 6, but not T helper 2 cytokines, promotes lung carcinogenesis. Cancer. Prev Res (Phila) 4: 51-64. doi:10.1158/1940-6207.PREV-11-B51.
33. Song L, Rawal B, Nemeth JA, Haura EB (2011) JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther 10: 481-494. doi:10.1158/1535- 7163.MCT-10-0502. PubMed: 21216930.
34. Kim SM, Kwon OJ, Hong YK, Kim JH, Solca F et al. (2012) Activation of IL-6R/JAK1/STAT3 signaling induces De Novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol Cancer Ther 11: 2254-2264. doi:10.1158/1535-7163.MCT-12-0311. PubMed: 22891040.
35. Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B et al. (2010) TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A 107: 15535-15540. doi:10.1073/pnas.1009472107. PubMed: 20713723.
36. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359: 1367-1380. doi:10.1056/NEJMra0802714. PubMed: 18815398.
37. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K et al. (2007) LKB1 modulates lung cancer differentiation and metastasis. Nature 448: 807-810. doi:10.1038/nature06030. PubMed: 17676035. (Pubitemid 47266337)
38. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M et al. (1994) Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368: 339-342. doi:10.1038/368339a0. PubMed: 8127368. (Pubitemid 24104268)
39. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D et al. (2001) Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15: 3243-3248. doi:10.1101/gad.943001. PubMed: 11751630. (Pubitemid 34008190)
40. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M et al. (2001) Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29: 418-425. doi:10.1038/ng747. PubMed: 11694875. (Pubitemid 34326692)
41. Fukuda K, Kobayashi A, Watabe K (2012) The role of tumor-associated macrophage in tumor progression. Front Biosci (Schol Ed) 4: 787-798. PubMed: 22202090.
42. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860-867. doi:10.1038/nature01322. PubMed: 12490959. (Pubitemid 36019639)
43. O'Hayer KM, Brady DC, Counter CM (2009) ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis. Carcinogenesis 30: 1841-1847. doi:10.1093/carcin/ bgp198. PubMed: 19805574.
44. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H et al. (2008) "Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med 205: 1261-1268. doi:10.1084/jem.20080108. PubMed: 18490490. (Pubitemid 351831483)
45. Meylan E, Dooley AL, Feldser DM, Shen L, Turk E et al. (2009) Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 462: 104-107. doi:10.1038/nature08462. PubMed: 19847165.
46. Mazieres J, He B, You L, Xu Z, Jablons DM (2005) Wnt signaling in lung cancer. Cancer Lett 222: 1-10. doi:10.1016/j.canlet.2004.08.040. PubMed: 15837535. (Pubitemid 40544841)
47. Suganuma M, Okabe S, Kurusu M, Iida N, Ohshima S et al. (2002) Discrete roles of cytokines, TNF-alpha, IL-1, IL-6 in tumor promotion and cell transformation. Int J Oncol 20: 131-136. PubMed: 11743653.
48. Balkwill F (2002) Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13: 135-141. doi:10.1016/S1359-6101(01)00020-X. PubMed: 11900989.
49. Kleeff J, Kusama T, Rossi DL, Ishiwata T, Maruyama H et al. (1999) Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int J Cancer 81: 650-657. doi:10.1002/(SICI)1097-0215(19990517)81:4. PubMed: 10225458. (Pubitemid 29203066)
50. Ott TR, Lio FM, Olshefski D, Liu XJ, Struthers RS et al. (2004) Determinants of high-affinity binding and receptor activation in the Nterminus of CCL-19 (MIP-3 beta). Biochemistry 43: 3670-3678. doi:10.1021/bi035895h. PubMed: 15035637. (Pubitemid 38391721)
51. Ma Y, Shurin GV, Gutkin DW, Shurin MR (2012) Tumor associated regulatory dendritic cells. Semin Cancer Biol 22: 298-306. doi:10.1016/j.semcancer.2012.02. 010. PubMed: 22414911.
52. Amedei A, Della Bella C, Silvestri E, Prisco D, D'Elios MM (2012) T cells in gastric cancer: friends or foes. Clin Dev Immunol 2012:690571.